Needham & Company Maintains Buy on Hyperion Therapeutics (HPTX) Post Q4

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Needham & Company reiterated its Buy rating and $25 price target on Hyperion Therapeutics (NASDAQ: HPTX) following Q4 results.

The analyst reminds clients that Ravicti was approved on 2/1/13 for the treatment of Urea Cycle Disorders. Launch is still planned prior to the end of April 2013. The sales force has been hired and efforts are underway with payers around coverage, they said.

"We expect the company to continue discussions with the FDA in 2013 around the design of a Phase 3 program in Hepatic Encephalopathy (HE)," the analyst notes. "A trial is expected to begin by YE13"

For an analyst ratings summary and ratings history on Hyperion Therapeutics click here. For more ratings news on Hyperion Therapeutics click here.

Shares of Hyperion Therapeutics closed at $19.14 yesterday, with a 52 week range of $9.95-$23.47.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
• Compuware (CPWR) Estimates Trimmed, PT Raised at Jefferies
• Goldman Sachs Downgrades Aixtron (AIXG) to Neutral

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Needham & Company

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?